Viewing Study NCT04828057


Ignite Creation Date: 2025-12-24 @ 6:59 PM
Ignite Modification Date: 2025-12-30 @ 10:21 PM
Study NCT ID: NCT04828057
Status: COMPLETED
Last Update Posted: 2022-10-31
First Post: 2021-03-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Sponsor: Santen Pharmaceutical (Taiwan) Co., LTD
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ocular Surface Disease View
None Primary Open Angle Glaucoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None tafluprost View
None Tapcom-s View
None switching View